These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 37904659)

  • 1. Drug-Eluting Bead Transarterial Chemoembolization Versus Radiofrequency Ablation as an Initial Treatment of Single Small (≤ 3 cm) Hepatocellular Carcinoma.
    Lee S; Jeong YY; Lee BC; Shin SS; Heo SH; Kim HO; Park C; Jeong WG
    J Korean Med Sci; 2023 Oct; 38(42):e362. PubMed ID: 37904659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
    Zhu D; Yuan D; Wang Z; Chen S
    Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression.
    Cao S; Zou Y; Lyu T; Fan Z; Guan H; Song L; Tong X; Wang J
    Int J Hyperthermia; 2022; 39(1):1-7. PubMed ID: 34937501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation.
    Wang X; Liang H; Lu Z
    Minim Invasive Ther Allied Technol; 2020 Dec; 29(6):344-352. PubMed ID: 31375044
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.
    Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM
    BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors.
    Zhang H; Wu C; Chen M; Sun Y; Han J
    J Cancer Res Ther; 2023 Dec; 19(6):1525-1532. PubMed ID: 38156918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
    Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
    BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
    Li N; Chen J
    Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival.
    Lee DH; Lee JM; Kim PN; Jang YJ; Kang TW; Rhim H; Seo JW; Lee YJ
    Eur Radiol; 2019 Sep; 29(9):5052-5062. PubMed ID: 30770968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Li C
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101535. PubMed ID: 33121882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellular carcinoma: a pilot non-randomized trial.
    Kim TH; Kim NH; Kim JD; Kim YN; Kim YJ; Kim EJ; Yoo KD; Ryu CH; Song HH; Kim H
    J Liver Cancer; 2021 Sep; 21(2):146-154. PubMed ID: 37383084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study.
    Kim JG; Cho SK; Hyun D; Shin SW; Park KB; Park HS; Choo SW; Do YS; Woo SY; Baek SY
    Abdom Radiol (NY); 2021 Dec; 46(12):5735-5745. PubMed ID: 34581928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.
    Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M
    Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation.
    Hyun D; Cho SK; Shin SW; Park KB; Park HS; Choo SW; Do YS; Choo IW; Lee MW; Rhim H; Lim HK
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):417-25. PubMed ID: 26246215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naïve hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes.
    Hyun D; Cho SK; Shin SW; Park KB; Lee SY; Park HS; Do YS
    Acta Radiol; 2018 Jul; 59(7):773-781. PubMed ID: 29034691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
    Bai XM; Cui M; Yang W; Wang H; Wang S; Zhang ZY; Wu W; Chen MH; Yan K; Goldberg SN
    Radiology; 2021 Aug; 300(2):458-469. PubMed ID: 34003058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.